DUBAI, United Arab Emirates--(BUSINESS WIRE)--Boehringer Ingelheim announced today the launch of the GLORIATM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.